Evidence map›Paper›PMID 36780706›Full record

ArticleACS chemical neuroscience2023

Synthesis and Pharmacological Characterization of a Difluorinated Analogue of Reduced Haloperidol as a Sigma-1 Receptor Ligand.

Run-Duo Gao, Michelle Taylor, Tamara McInnis, Zhenglan Chen, Sadakatali S Gori, Heather M LaPorte, Maxime A Siegler, Janet L Neisewander, Robert H Mach, Meharvan Singh and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Run-Duo GaoJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Michelle TaylorDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, United States.
Tamara McInnisDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, United States.
Zhenglan ChenDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, United States.
Sadakatali S GoriJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Heather M LaPorteDepartment of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153, United States.
Maxime A SieglerDepartment of Chemistry, The Johns Hopkins University, Baltimore, Maryland 21218, United States.ORCID 0000-0003-4165-7810
Janet L NeisewanderSchool of Life Sciences, Arizona State University, Tempe, Arizona 85287, United States.
Robert H MachDepartment of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.ORCID 0000-0002-7645-2869
Meharvan SinghDepartment of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153, United States.
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.ORCID 0000-0001-9814-4157
Rana RaisJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.ORCID 0000-0003-4059-2453
Robert R LuedtkeDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, United States.
Takashi TsukamotoJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.ORCID 0000-0002-0216-7520
Johns Hopkins University · USUniversity of North Texas · USLoyola University Chicago · USArizona State University · USUniversity of Pennsylvania · US

Funding

Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Leah Helane Rubin · 2006 to 2026
$33.2M
Discovery of functionally selective Alzheimer's disease therapeuticsR01AG055072 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI SCHREIHOFER, DEREK A · 2017 to 2021
$3.2M
NIA NIH HHS R01 AG055072NIMH NIH HHS P30 MH075673
6 · The paper itself

Abstract

Reduced haloperidol (

Indexed as

HaloperidolReceptors, sigmaAnimalsBrain-Derived Neurotrophic FactorLigandsMiceSigma-1 Receptor4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanolBrain-Derived Neurotrophic FactorHaloperidolLigandsReceptors, sigmaSigma-1 Receptoractive avoidance taskbrain-derived neurotrophic factor (BDNF)drug metabolismfluorinated moleculesreduced haloperidolsigma-1 receptor

Identifiers

PMID36780706
PMCPMC11622112
OpenAlexW4320483612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.